FDA enforcing QbD from 2013 [Dissolution / BCS / IVIVC]

posted by Helmut Homepage – Vienna, Austria, 2012-01-19 16:48 (5258 d 09:59 ago) – Posting: # 7966
Views: 4,511

Dear ElMaestro!

❝ What's your take on this?


Ooh–ooh! We discussed the draft already last year. Saw one presentation by a representative of the FDA last year (forgot where…) – seemed to be very serious about “That’s the way to go!”.
Would be tough to meet these requirements. Could FDA really reject an ANDA if BE was demonstrated in vivo, similar dissolution (f2), and an established IVIVC if the development was not done according to their interpretation (sic!) of Section 2.1 of ICH Q8(R2)? Any lawyers around?

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
128 visitors (0 registered, 128 guests [including 47 identified bots]).
Forum time: 03:47 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5